Levodopa-carbidopa intestinal gel decreases dyskinesia in patients with Parkinson's Disease: Study

The key finding of this study are:

1. After 12 weeks, dyskinesias assessed by UDysRS were considerably lower in the LCIG group (n = 24; 17.37 2.79) compared to the OMT group (n = 26; 2.33 2.56) (15.05 3.20).

2. At week 12, LCIG outperformed OMT in "On" time without bothersome dyskinesia, QoL, general impression of change, activities of daily living, and Unified Parkinson's Disease Rating Scale (UPDRS) Part III.

3. In 27 (44.3%) of the patients, treatment-emergent adverse events were recorded (LCIG, 18 [64.3% ]; OMT, 9 [27.3% ]). Two (7.1%) of the LCIG-treated individuals experienced serious adverse events.

In conclusion, the findings support some of the effectiveness findings for LCIG and demonstrate benefit in comparison to dyskinesia as measured directly with dyskinesia-specific metrics. The findings also provide information on the potential side effects of this treatment.

Reference:

Freire‐Alvarez, E., Kurča, E., Lopez Manzanares, L., Pekkonen, E., Spanaki, C., Vanni, P., Liu, Y., Sánchez‐Soliño, O., & Barbato, L. M. (2021). Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial. In Movement Disorders (Vol. 36, Issue 11, pp. 2615–2623). Wiley. https://doi.org/10.1002/mds.28703